Vestal Point Capital, LP Reports 5.4% Passive Stake in Enliven Therapeutics (ELVN)

On May 15, 2026, Vestal Point Capital, LP filed a Schedule 13G/A with the SEC, reporting a significant stake in Enliven Therapeutics, Inc. (ELVN). The filing indicates that as of March 31, 2026, the reporting persons—including Vestal Point Capital, LP and Ryan Wilder (Chief Investment Officer)—beneficially own 3,250,000 shares of common stock. This position represents approximately 5.4% of the company's outstanding shares, based on 59,800,406 shares reported as of February 19, 2026. The filing serves as an amendment to a previous statement and confirms that the shares are held in the ordinary course of business by the Vestal Point Fund and a managed account. The reporting persons share voting and dispositive power over the reported securities. This acquisition moves Vestal Point Capital into a passive ownership position exceeding the 5% threshold, though the filing specifies that the securities were not acquired for the purpose of changing or influencing the control of the issuer.